

Oliver Politz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2525175/publications.pdf>

Version: 2024-02-01

4
papers

155
citations

1937685

4
h-index

2272923

4
g-index

4
all docs

4
docs citations

4
times ranked

354
citing authors

#	ARTICLE	IF	CITATIONS
1	Rogaratinib: A potent and selective pan-EGFR inhibitor with broad antitumor activity in EGFR-overexpressing preclinical cancer models. <i>International Journal of Cancer</i> , 2019, 145, 1346-1357.	5.1	65
2	BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. <i>International Journal of Cancer</i> , 2017, 140, 449-459.	5.1	51
3	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. <i>Blood Advances</i> , 2020, 4, 819-829.	5.2	28
4	Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1289-1297.	4.1	11